We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS to Create Oncology Drug Powerhouse With Celgene Acquisition
BMS to Create Oncology Drug Powerhouse With Celgene Acquisition
Bristol-Myers Squibb’s planned acquisition of Celgene this year will dramatically increase BMS’ position in oncology drugs as it absorbs the New Jersey-based company’s portfolio of existing cancer drugs and promising pipeline products.